Induction Healthcare Group PLC (AIM:INHC) said commercial revenues for the year ending 31 March 2023 will be up 12% on a pro-forma basis at £13.8mln.
Costs are also being tightly managed, said the app-based health platform, with overheads down by 30% on a monthly basis compared to a year ago.
Induction added it is on track to hit its target of self-sustaining growth and cash break-even in 2024.
Revenues included a full year from the Attend Anywhere acquisition that on a pro-forma basis rose 9.4% to £10.8mln, while Induction Zesty sales jumped 87% to £2.1mln as the take-up of digital appointments by the NHS increased.
James Balmain stepped down as chief executive in January and Induction added that Hugo Stephenson will also resign as a non-executive director in May at the end of his current term.
Christopher Samler, chair, said: “It has been a challenging time during which we have reduced our cost base to reflect a self-sustaining and focused business.
“As a result, Induction Healthcare is now in far better shape to provide our customers with the advanced products they need."
Net cash in the business was £4.2mln (2022: £7.5mln) at the year end.